A Phase 1b, Open-Label, Exploratory Study Evaluating the Effects of Inhaled Epinephrine in Individuals Experiencing Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges

The goal of this exploratory study is to evaluate the effects of inhaled epinephrine in subjects, who may not be eligible for the GHL-101 trial, and who are experiencing systemic allergic reaction (SAR) that occur following allergy testing, subcutaneous immunotherapy (SCIT), oral challenges (with food and/or drug) or oral immunotherapy (OIT).

Start Date25 Aug 2025

Sponsor / Collaborator

Kokua Pharma Inc

NCT07084753

/ Not yet recruitingNot ApplicableIIT

Comparison of Opioid-based Anesthesia, Opioid-free Anesthesia Based on Intravenous Drugs and Opioid-free Anesthesia With Thoracic Paravertebral Block, in Patients Undergoing Laparoscopic Gastric Bypass Surgery for Obesity

Regional anesthesia is a technique in which a local anesthetic is injected near a nerve or spinal cord to block sensation, motor stimulation, and pain. In this study, an ultrasound-guided paravertebral block will be used, with careful consideration of all positive and negative factors and possible complications. A thoracic paravertebral block is performed by inserting a needle into the intercostal spaces on the back, approximately 4 cm lateral to the spine. Many studies support excellent pain control with this technique, during and after surgery in thoracic and abdominal surgery. Investigators aim to achieve faster patient mobility after surgery, rapid recovery of bowel function, reduced nausea and vomiting, and maximum pain control. The use of opioids, which can additionally cause respiratory suppression and drowsiness, is avoided.
At any time in case of need to switch from laparoscopic to open surgery, equally adequate anesthesia and postoperative analgesia are ensured without the need to change the approach to the same. In this study, the basic scientific assumption (hypothesis) of the researchers is that non-opioid anesthesia with thoracic paravertebral block provides adequate pain control during and long-term after the surgical procedure, without the side effects of opioid anesthesia.
The main goal of the study is to determine which type of anesthesia results in the best pain control and most significantly reduces complications of anesthesia and surgery in overweight patients who are scheduled for laparoscopic longitudinal gastrectomy and partial/total gastrectomy.

Start Date30 Jul 2025

Sponsor / Collaborator

University Hospital Dubrava

NCT07073209

/ RecruitingNot ApplicableIIT

PENG vs Femoral Block for Hip Fracture, A Pragmatic Cluster-Randomized Study

This study aims to compare the Pericapsular Nerve Group (PENG) block with femoral block for hip fracture pain. Participants presenting to the hospital with a diagnosis of hip fracture and consenting to analgesic block will receive either a PENG or femoral block. The choice of block will be dictated by a randomized monthly schedule, and all participants presenting during each four-week period will receive the designated block. A sub-group analysis will be performed to determine any difference in efficacy in participants with intracapsular versus extracapsular fractures.

Start Date10 Jul 2025

Sponsor / Collaborator

Weill Medical College of Cornell University

100 Clinical Results associated with Adrenaline

100 Translational Medicine associated with Adrenaline

100 Patents (Medical) associated with Adrenaline

46,584

Literatures (Medical) associated with Adrenaline

31 Dec 2025·SCANDINAVIAN CARDIOVASCULAR JOURNAL

Ex vivo resuscitation and evaluation of hearts after 22 minutes of normothermic cardiac arrest

Article

Author: Li, Mei ; Steen, Erik ; Steen, Stig ; Pascevivius, Audrius ; Liao, Qiuming

OBJECTIVE:

The aim was to resuscitate and evaluate hearts ex vivo after 22 min of cardiac arrest with the goal of increasing the number of usable hearts from controlled donation after circulatory death (cDCD).

DESIGN:

Eight pigs (39-61 kg) underwent 22 min of ventricular fibrillation, after which the heart was first perfused in vivo for three minutes with an oxygenated, erythrocyte-containing cardioplegic preservation solution. The heart was then explanted and perfused ex vivo with the same solution for three hours at 18 °C in a transportable heart preservation system. Functional evaluation was performed ex vivo (n = 7), while one heart underwent orthotopic transplantation and was monitored for 24 h.

RESULTS:

The seven hearts evaluated ex vivo easily pumped twice the cardiac output measured in vivo. The transplanted heart maintained normal blood pressure, blood gases, and urine output throughout the 24-hour observation period. At the end of this period the aortic pressure was 104/80 mmHg with a heart rate of 129 beats per minute. Intravenous administration of 20, 40, and 100 µg adrenaline resulted in an aortic pressures of 238/171, 284/196, and 287/201 mmHg with corresponding heart rates of 162, 188, and 223 beats per minute.

CONCLUSION:

Hearts exposed to 22 min of cardiac arrest were successfully resuscitated ex vivo and demonstrated adequate function when evaluated.

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations

Review

Author: Keene, Sharon A. ; Gupta, Aditya K. ; Talukder, Mesbah

Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.

01 Nov 2025·TALANTA

Synthesis of ternary heterostructured rice-stick-like Ag/polyoxometalates/nitrogen-doped carbon nanotube hybrids for the sensitive detection of adrenaline

Article

Author: Yang, Xinjian ; Shen, Wei ; Hao, Lin ; Zhang, Yufan ; Liu, Lin

This study presents the innovative design and synthesis of rice-stick-like Ag/polyoxometalates/nitrogen-doped carbon nanotubes (Ag/POM/N-CNTs) using an efficient and mild reduction method. N-CNTs are first synthesized through a self-degrading template method followed by the carbonization of polypyrrole nanotubes (PPy-NTs). The N-CNTs exhibit excellent characteristics, including a high length-to-diameter ratio and an interconnected nanotube structure, which shorten the electron transport distance and enhance electrochemical properties. During the process of loading Ag nanoparticles (Ag NPs) onto the N-CNTs, POM serves as both a reducing and linking agent. The synergistic effect between Ag species and N-CNTs significantly improves the catalytic performance of the nanohybrids. As a result, the Ag/POM/N-CNT-based electrochemical sensor demonstrates exceptional performance in adrenaline detection, with a broad linear range (0.40-700 μM), a low detection limit (0.30 μM, S/N = 3), and a sensitivity of 3.13 μA μM^-1. In addition to these advantages, the composite material also exhibits excellent specificity and stability, strongly indicating the practical application potential of Ag/POM/N-CNTs in adrenaline detection.

365

News (Medical) associated with Adrenaline

09 Sep 2025

·www.biospace.com

Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’

iStock, Mintr Regeneron’s antibody duos significantly lowered eye itching and redness, as well as pin prick reactivity, in people with cat and birch allergies. Still, BMO Capital Markets expressed uncertainty about the assets’ “commercial potential in a highly generic market.” Regeneron’s investigational allergen-blocking antibodies have successfully eased symptoms in two separate late-stage studies of cat and birch pollen allergies. Writing to investors on Monday, analysts at BMO Capital Markets said Regeneron’s “antibody cocktails” resulted in “robust reductions” in various allergy symptoms, including eye itchiness and redness. BMO is “broadly impressed by the strength” of Regeneron’s findings, though the firm remains uncertain about the assets’ “commercial potential in a highly generic market.” In the cat study, Regeneron tested a combination of two antibodies—REGN1908 and REGN1909—designed to target the most dominant cat allergen, a molecule called FeID1. Results showed that ocular itch was cut by 52% versus placebo, assessed one week after treatment. REGN1908 and REGN1909 likewise significantly eased conjunctival redness and skin prick reactivity, with respective effect sizes of 39% and 44%. The antibody combo had stronger efficacy in study participants whose allergies were first confirmed to have been driven by FeID1, resulting in a 65% drop in ocular itching. Similarly, Regeneron tested two other antibodies, REGN5713 and REGN5715, designed to target BetV1, the dominant allergenic birch pollen protein. Results likewise demonstrated “impressive” symptom reduction, according to BMO, with a 51% decrease in eye itching. Conjunctival redness and skin prick reactivity dropped by 46% and 44%, respectively. In both studies, Regeneron’s antibody cocktails were safe and well-tolerated, with no dropouts linked to serious treatment-related adverse events. The pharma expects to launch additional late-stage trials later this year for birch allergy and in the first half of 2026 for cat allergy. Despite these two late-stage wins, BMO raised questions regarding the market prospects of Regeneron’s antibodies. “Commercialization story remains uncertain,” the analysts wrote. “While we do not discount the number of sufferers of allergies, we need to hear more about a potential commercial strategy for Regeneron to penetrate this market, which is heavily dominated by generics like antihistamines.” Elsewhere in the allergy space, ARS Pharmaceuticals in March won the FDA’s go-ahead for the nasal-spray version of its epinephrine drug neffy, indicated for type I allergic reactions, including anaphylaxis, in children. The approval opened up the use of neffy 1-mg to kids 4 years and older who weigh from 15 kg to less than 30 kg.

Clinical ResultDrug Approval

08 Sep 2025

·www.globenewswire.com

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy Results suggest real-world effectiveness of neffy is consistent with that historically reported for epinephrine injection SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today shares real-world evidence evaluating the clinical performance of neffy® (epinephrine nasal spray) in patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy. These findings represent the first large-scale analysis of treatment outcomes with neffy during routine clinical practice and was accepted in August for publishing as a correspondence in the Annals of Allergy, Asthma and Immunology, the official journal of the American College of Allergy, Asthma and Immunology. Nearly 90% (89.2%) of 545 patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy were successfully treated with a single dose of neffy by a healthcare provider. Meta-analyses report a similar proportion of patients, 88.9%, being successfully treated with a single dose of epinephrine intramuscular injection or auto-injector by a healthcare provider for food-induced anaphylaxis.1 This highly similar treatment success rate supports that the real-world clinical effectiveness of neffy in anaphylaxis is consistent with epinephrine injection. Importantly, these real-world data build upon previously published clinical evidence, including a prospective Phase 3 study2 (n = 15 patients) assessing the efficacy of neffy for the treatment of oral food challenge-induced anaphylaxis symptoms. In that study, no patients required a second dose of neffy for treatment of the initial anaphylactic reaction. “These data reinforce existing findings and is the first large-scale report of real-world treatment outcomes with neffy during anaphylaxis events. The finding that about 9 out of every 10 patients were successfully treated with a single dose of neffy in more than 500 patients is essentially identical to the historic response rates observed with epinephrine injection,” said Dr. Thomas B. Casale, M.D., Professor of Medicine and Pediatrics and Chief of Clinical and Translational Research in the USF Health Morsani College of Medicine's Division of Allergy and Immunology at the University of South Florida in Tampa, Florida. “We believe these real-world outcomes data support the clinical interchangeability of neffy and epinephrine injection, building on the clinical studies conducted for FDA approval that showed neffy achieved blood levels and pharmacodynamic responses within the range of approved injection products.” Figure 1: Treatment success rate with a single dose of neffy administered by a healthcare provider during oral food challenge and allergen immunotherapy during the neffy experience program (n = 545 patients) compared to historic control treatment success rate with a single dose of epinephrine injection administered by a healthcare provider during food-induced anaphylaxis as reported by Patel et. al. JACI, 2021 (n = 12,615 patients). About the neffy Experience Program The data from this retrospective observational analysis was collected from healthcare providers participating in the neffy experience program. In the neffy experience program, healthcare providers were given six doses of neffy for use to rescue patients experiencing anaphylaxis symptoms during oral food challenge or allergen immunotherapy. neffy labeling states that a second dose should be administered if anaphylaxis symptoms continue or get worse starting 5 minutes after the first dose. As of the March 2025 data cut-off, 301 healthcare providers had responded to the survey instrument, and a total of 545 patients were reported having been treated with neffy 2 mg. Four hundred and eighty-six (486) of these patients had been successfully treated with a single dose of neffy 2 mg, with the remaining 59 patients requiring a second dose of epinephrine. The neffy experience program is actively ongoing and now includes both the 2 mg and 1 mg doses. This data from the neffy experience program is consistent with clinical trials recently published on the real-world clinical effectiveness of neffy. However, this observational analysis differs from a randomized clinical trial in several ways. The studies have different endpoints and there are inherent limitations in real-world observational studies, including lack of randomization, lack of uniform timing or type of clinical assessments and challenges with missing data. About neffy® neffy is a nasal spray used for emergency treatment of allergic reactions including anaphylaxis, in adults and children aged 4 years and older who weigh 33 lbs. or greater. INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray) INDICATION neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 33 lbs. or greater. IMPORTANT SAFETY INFORMATIONneffy contains epinephrine, a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or other unknown causes. Always carry two neffy nasal sprays with you because you may not know when anaphylaxis may happen and because you may need a second dose of neffy if symptoms continue or come back. Each neffy contains a single dose of epinephrine. neffy is for use in the nose only. Use neffy right away, as soon as you notice symptoms of an allergic reaction. If symptoms continue or get worse after the first dose of neffy, a second dose is needed. If needed, administer a second dose using a new neffy in the same nostril starting 5 minutes after the first dose. Get emergency medical help for further treatment of the allergic emergency (anaphylaxis), if needed after using neffy. Tell your healthcare provider if you have underlying structural or anatomical nasal conditions, about all the medicines you take, and about all your medical conditions, especially if you have heart problems, kidney problems, low potassium in your blood, Parkinson’s disease, thyroid problems, high blood pressure, diabetes, are pregnant or plan to become pregnant, or plan to breastfeed. Tell your healthcare provider if you take or use other nasal sprays or water pills (diuretics) or if you take medicines to treat depression, abnormal heart beats, Parkinson’s disease, heart disease, thyroid disease, medicines used in labor, and medicines to treat allergies. neffy and other medications may affect each other, causing side effects. neffy may affect the way other medicines work, and other medicines may affect how neffy works. neffy may cause serious side effects. If you have certain medical conditions or take certain medicines, your condition may get worse, or you may have more or longer lasting side effects when you use neffy. Common side effects of neffy include: nasal discomfort, headache, throat irritation, chest and nasal congestion, feeling overly excited, nervous or anxious, nose bleed, nose pain, sneezing, runny nose, dry nose or throat, tingling sensation, including in the nose, feeling tired, dizziness, nausea, and vomiting. Tell your healthcare provider if you have any side effects that bother you or that do not go away after using neffy. These are not all of the possible side effects of neffy. Call your healthcare provider for medical advice about side effects. To report side effects, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see the full Prescribing Information and Patient Information for neffy. About Type I Allergic Reactions Including Anaphylaxis Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine auto-injectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine auto-injector prescription, and of those, only half consistently carry their prescribed auto-injector. Even if patients or caregivers carry an auto-injector, more than half either delay or do not administer the device when needed in an emergency. About ARS Pharmaceuticals, Inc. ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com. Forward Looking Statements Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: expectations and evaluations regarding the clinical performance and patient benefits of neffy, including its needle-free, portable and easy to use design; the belief that real-world outcomes data support the clinical interchangeability of neffy and epinephrine injection; and the beliefs that such data will continue to build on the clinical studies of neffy conducted for FDA approval that showed neffy achieved blood levels and pharmacodynamic responses within the range of approved epinephrine injection products and on previously published clinical evidence, including a prospective Phase 3 study assessing the efficacy of neffy for the treatment of oral food challenge-induced anaphylaxis symptoms; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “believe,” “can,” “could,” “expect,” “if,” “may,” “potential,” “plan,” “will,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from neffy; the ability to maintain regulatory approval for neffy in its currently approved indications; the scope, progress and expansion of developing and commercializing neffy; the scope, progress and expansion of developing our intranasal epinephrine technology; clinical trial results; the potential for governments and payors to delay, limit or deny coverage for neffy; the size and growth of the market for neffy and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharma’s ability to protect its intellectual property position; and the impact of government laws, regulations and policies. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in ARS Pharma’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on May 14, 2025 and in ARS Pharma’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 13, 2025. These documents can also be accessed on ARS Pharma’s website at www.ars-pharma.com by clicking on the link “Financials & Filings” under the “Investors & Media” tab. The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law. For more information, visit www.ars-pharma.com, and follow us on LinkedIn and X. Investor Contact:Justin Chakma, ARS Pharmajustinc@ars-pharma.com Media Contact:Christy Curran, Sam Brown Inc.christycurran@sambrown.com615.414.8668 References 1 Patel N, Chong KW, Yip AYG, Ierodiakonou D, Barta J, Boyle RJ, et al. Use of multiple epinephrine doses in anaphylaxis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2021;148(5):1307-1315. 2 Ebisawa M, Takahashi K, Takahashi KK, Yanagida N, Sato S, Lieberman J, et al. Epinephrine nasal spray improves allergic symptoms in patients undergoing oral food challenge, phase 3 trial. J Allergy Clin Immunol. 2025; doi:10.1016/j.jaip.2025.06.038. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/890e02e2-e6bc-4c22-a1cf-a5b0a47fc286

Clinical ResultPhase 3Immunotherapy

08 Sep 2025

·ir.alk.net

Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray

ALK (ALKB:DC / OMX: ALK B) today announced that real-world evidence evaluating the clinical performance of the nasal adrenaline spray neffy® in US patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy has been accepted for scientific publication. The findings represent the first large-scale analysis of treatment outcomes with neffy® during routine clinical practice and were accepted for publishing as a correspondence in the Annals of Allergy, Asthma and Immunology, the official journal of the American College of Allergy, Asthma and Immunology. The analysis showed that 89.2% of 545 patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy were successfully treated with a single dose of neffy®by a healthcare provider, while 10.8% of the 545 patients required a second dose. These results suggest real-world effectiveness of neffy® to be consistent with historic response rates observed with adrenaline injection that report a similar proportion of patients, 88.9%, being successfully treated with a single dose of adrenaline intramuscular injection or auto-injector by a healthcare provider for food-induced anaphylaxis, and 11.1% of patients requiring a second dose. neffy® is a ready to use, needle-free nasal adrenaline spray approved for timely emergency anaphylaxis treatment developed by US-based ARS Pharmaceuticals, Inc. Based on the license agreement entered in November 2024, ALK holds exclusive global rights to commercialise neffy® (branded EURneffy® in the EU and the UK) with exception of the USA, Australia, New Zealand, Japan, and China. In May 2025, the partnership was extended to include a co-promotion agreement in the USA. The EURneffy® nasal adrenaline spray was launched in the first EU market, Germany, in the end of June 2025 and additional launches are planned before year-end. The observational analysis was based on data collected from healthcare providers participating in the neffy® experience program. Healthcare providers were given six doses of neffy®for use to rescue patients experiencing anaphylaxis symptoms during oral food challenge or allergen immunotherapy. neffy® US labelling states that a second dose should be administered if anaphylaxis symptoms continue or get worse starting 5 minutes after the first dose. As of the March 2025 data cut-off, 301 healthcare providers had responded to the survey instrument, and a total of 545 patients were reported having been treated with neffy® 2 mg. 486 of these patients had been successfully treated with a single dose of neffy® 2 mg, with the remaining 59 patients requiring a second dose of adrenaline. The neffy® experience program is actively ongoing and now includes both the 2 mg and 1 mg doses. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net. Attachment InvestorNews_08September25_neffy real-world evidence

License out/inImmunotherapyClinical ResultDrug ApprovalClinical Study

100 Deals associated with Adrenaline

External Link

KEGG	Wiki	ATC	Drug Bank
D00095	Adrenaline	C01CA24 B02BC09 S01EA01	DB00668

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Intermittent asthma	United States	Armstrong Pharmaceuticals, Inc.	07 Nov 2018
Mydriasis	United States	Ph Healthcare Services	07 Dec 2012
Hypersensitivity	United States	Viatris Specialty LLC	22 Dec 1987
Anesthesia	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Bronchial Spasm	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Hemorrhage	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Hypotension	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Shock	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Anaphylaxis	China	Grand Pharmaceutical Group	01 Jan 1981
Heart Arrest	China	Grand Pharmaceutical Group	01 Jan 1981
Asthma	United States	Wyeth Consumer Healthcare LLC	08 Nov 1967

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Persistent asthma	Phase 2	United States	ARS Pharmaceuticals, Inc.	28 Jul 2022
Urticaria	Phase 2	United States	ARS Pharmaceuticals, Inc.	28 Jul 2022
Hypersensitivity, Immediate	Phase 2	Canada	Aquestive Therapeutics, Inc.	12 Jul 2022
Drug Hypersensitivity	Phase 1	Sweden	Orexo AB	22 Apr 2024
Rhinitis, Allergic	Phase 1	China	ARS Pharmaceuticals Operations, Inc.	17 Mar 2023
Rhinitis, Allergic	Phase 1	China	Pediatrix Therapeutics (Shanghai) Co.,Ltd.	17 Mar 2023
Respiratory Tract Infections	Phase 1	Australia	ARS Pharmaceuticals, Inc.	09 Aug 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02722746 (Pilot epinephrine dose-finding study, CTgov)	Phase 1/2	Analgesia \| Hypotension	66	Ropivacaine (Ropivacaine Only Control Group)	oktywjkoqp: percent difference = 20.8 (95% CI, -8.9 to 47.3), P-Value = 0.165	-	18 Jun 2025
				Ropivacaine+Epinephrine (Ropivacaine + 2 mcg/mL Epinephrine)
CTIS2024-514037-38-00 (OX640-002, Company_Website) Manual	Not Applicable	Rhinitis, Allergic	30	OX640	gtzyfyohhh(hpylcxxzwv) = Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. hvmcsrryzc (wzunzibkrg ) View more	Positive	10 Jan 2025
				0.3 mg intramuscular epinephrine
GlobeNewswire Manual	Not Applicable	Oral allergy syndrome	-	Anaphylm (with allergen exposure)	lcwgjeemwu(melesmlpid) = no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. lvzytudqzn (sfmkaecafk ) Met View more	Positive	24 Oct 2024
				Anaphylm (without allergen exposure)
NCT04207840 (Pubmed \| J Aerosol Med Pulm Drug Deliv)	Phase 4	Asthma \| Anaphylaxis	28	Epinephrine MDI	whachnwxqf(mkdnaxqnvi) = wqvijrypgv ovjhajnpjh (vknfliktdl )	Positive	29 Aug 2024
				Epinephrine IM	whachnwxqf(mkdnaxqnvi) = lbszqvhrtp ovjhajnpjh (vknfliktdl )
NCT03126968 (PROPHET, CTgov)	Phase 2/3	Hemorrhage \| Lung transplant rejection \| Hemoptysis	66	Topical epinephrine (Prophylactic Topical Epinephrine)	wwbfepviyb = laflxvcjrf yojwjxucdo (puwiwhtwhp, ofgksotiif - hzjnrrzluh) View more	-	28 Aug 2024
				Placebos (Placebo)	wwbfepviyb = qsvrvuwgtg yojwjxucdo (puwiwhtwhp, fvsjktuhik - ucbwysfpob) View more
GlobeNewswire Manual	Not Applicable	Hypersensitivity	36	Anaphylm™ (epinephrine) Sublingual Film	czepxiliun(mrsdksofor) = ocajxqghlu cdwnypbrnm (acuwbprvup ) Met	Positive	25 Jul 2024
				Adrenalin manual intramuscular (IM) injection	czepxiliun(mrsdksofor) = zuaojhyzaf cdwnypbrnm (acuwbprvup ) Met
NCT02722746 (Pilot epinephrine dose-finding study, Pubmed)	Phase 1/2	Hypotension	-	Epidural ropivacaine 0.2% without epinephrine	ioaxhjmfhv(vcbuxjjaxa) = gzvjhdqvvt roqakbqico (tqkrlxewnt )	Negative	11 Jul 2024
				Epidural ropivacaine 0.2% + 2 µg/mL epinephrine	ioaxhjmfhv(vcbuxjjaxa) = bvqssxnvij roqakbqico (tqkrlxewnt )
NCT05881915 (MD-245-2022, Pubmed)	Not Applicable	Hypotension	98	Epinephrine infusion (0.03 mcg/kg/min)	anzyyqlsik(pdclrmfczt) = rtjfrxqpao jsztrmacak (evjjzcfdpi )	Positive	25 May 2024
				Phenylephrine infusion (0.4 mcg/kg/min)	anzyyqlsik(pdclrmfczt) = zintijhxif jsztrmacak (evjjzcfdpi )
GlobeNewswire Manual	Phase 3	Hypersensitivity	100	Anaphylm (single dosing part)	uiswrhjvmj(ybgawvnjjt) = nzuitwbflq bytbwkrdce (uiaxmjyzdq ) View more	Positive	14 Mar 2024
				Anaphylm (repeat dosing part)	mjwaaqdurn(uiwvydletb) = mychhckzer ahryeyymgq (cwucbbrdjt ) View more
JPRN-jRCT2031230143 (AAAAI 12024 \| AAAAI 22024) Manual	Phase 3	Hypersensitivity \| Anaphylaxis	15	neffy 1.0mg	nrdcqttftl(wvmqwgezeh) = hzmlxhxunq eiwdhbpfxm (xrkjqiduhx ) View more	Positive	24 Feb 2024
				neffy 2.0mg	nrdcqttftl(wvmqwgezeh) = efuvwvcqbb eiwdhbpfxm (xrkjqiduhx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis